文献速递前列腺增生与排尿功能障碍

Aquablation治疗良性前列腺增生:6年真实世界前列腺体积相关性与出血事件

Aquablation for benign prostatic hyperplasia: real-world prostate size relevance and bleeding events across 6 years.
PubMed 文献 · BJU Int · 2025-12-15

平均前列腺体积87.3 mL,最大1189 mL,输血或重返手术室止血总体发生率为0.2%。结果表明Aquablation适用于广泛前列腺体积范围,真实世界安全性良好。

要点

  • Aquablation在6年间广泛用于各种前列腺体积,平均87.3 mL
  • 输血或重返手术室止血的总体发生率为0.2%
  • 真实世界数据显示该术式安全且适用性广

核心结论

  • Aquablation在广泛前列腺体积范围内持续应用,输血或重返手术室止血发生率低,真实世界安全性和适用性良好。

主要发现

  • 密度图分析显示研究各年份Aquablation在前列腺体积全范围内使用一致。
  • 输血或重返手术室行止血电凝的总体发生率为0.2%。

关键数值与推荐

  • 术后出血定义为输血或重返手术室行止血电凝。
  • 总体出血事件发生率为0.2%。

临床怎么用

  • 对于良性前列腺增生患者,Aquablation可考虑用于广泛前列腺体积范围,术后出血风险较低。

局限性

  • 数据来源于企业前瞻性数据库及FDA MAUDE数据库,可能存在报告偏倚和未完全覆盖真实世界事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To present large-scale safety outcomes, with a particular focus on postoperative bleeding following Aquablation for benign prostatic hyperplasia. PATIENTS AND METHODS: Patients who underwent Aquablation between 2019 and 2024 across Asia, Europe, and North America were assessed to evaluate trends in treated prostate sizes, which were visualised using density plots. A corporate prospective database was maintained, incorporating case recordings and data collected by on-site company representatives. In addition, the incidence of postoperative bleeding-defined as transfusion or surgical takeback for haemostatic fulguration-was analysed using data from the United States Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database and procedure counts by the manufacturer. RESULTS: A total of 70 270 Aquablation procedures were evaluated over the period from 2019 to 2024. The mean (standard deviation) prostate volume was 87.3 (42.4) mL, with a maximum recorded size of 1189 mL. Density plot analysis of prostate volumes demonstrated consistent utilisation of Aquablation across the full range of prostate sizes throughout all years studied. The overall rate of blood transfusion or return to the operating room for haemostatic fulguration was 0.2%, indicating a favourable safety profile across a very wide range of prostate sizes. CONCLUSIONS: Aquablation has been consistently utilised across a broad spectrum of prostate sizes, with a low overall rate of transfusion or return to the operating room for bleeding control. These findings highlight the procedure's broad applicability and favourable safety profile in real-world practice from 2019 to 2024.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bitar M, Ferreira R, Shprits S, et al. Aquablation for benign prostatic hyperplasia: real-world prostate size relevance and bleeding events across 6 years. BJU Int. 2025. PMID: 41399106. doi:10.1111/bju.70118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。